A Phase Ib/II, Open-Label Study of the Safety and Pharmacology of Atezolizumab Administered With or Without Bacille Calmette-Guérin in Patients With High-Risk Non−Muscle-Invasive Bladder Cancer
Phase of Trial: Phase I/II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Atezolizumab (Primary) ; BCG
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 10 Jul 2017 Planned End Date changed from 19 Jul 2018 to 27 Nov 2021.
- 10 Jul 2017 Planned primary completion date changed from 19 Jul 2018 to 7 Mar 2019.
- 17 Mar 2017 Planned End Date changed from 1 Jul 2018 to 19 Jul 2018.